Acknowledgement 

This activity is provided by Talem Health and RME Collaborative. 

 
This online program is recorded content from the live session at Oncology Congress Fall 2024 and is co-supported by independent medical education grants from AstraZeneca Pharmaceuticals; Daiichi Sankyo, Inc.; GSK; Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Pfizer, Inc. and Astellas. This activity is supported by an independent medical education grant from AstraZeneca Pharmaceuticals. 

Credit Available 

• Physicians — maximum of 1.0 AMA PRA Category 1 Credit™ 
• Nurses — 1.0 Contact Hour (0.75 contact hour of pharmacotherapy credit) 
• Pharmacists — 1.0 Contact Hour (0.1 CEU) 

All other healthcare professionals completing this course will be issued a statement of participation. 

Target Audience 

This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities. 

Program Overview 

The PI3K/AKT/PTEN pathway has emerged as a key player in breast cancer development. Notably, up to 50% of patients with hormone receptor–positive, human epidermal growth factor receptor 2–negative (HR+/HER2-) breast cancer have actionable biomarkers within this pathway, paving the way for novel approaches to management. This CME/CE activity will cover emerging therapeutic strategies for HR+/HER2- breast cancer that target the PI3K/AKT/PTEN pathway as well as best practices for enhancing early detection and management of treatment-related adverse events. Experts will also discuss ways to improve adherence to therapy and care coordination among rural and underserved populations using a multidisciplinary approach. 

This enduring activity is a recorded session from Oncology Congress that took place on September 28, 2024. 

Learning Objectives 

Upon completion of this activity, participants should be better able to:   

• Evaluate the efficacy and safety of current and emerging treatments for breast cancer that target the PI3K/AKT/PTEN pathway 
• Identify patients who may be eligible for treatment with inhibitors of the PI3K/AKT/PTEN pathway 
• Apply evidence-based strategies and best practices to identify, monitor, and manage adverse events associated with PI3K/AKT/PTEN pathway inhibitors 
• Develop a multidisciplinary approach to improve treatment adherence and care coordination in breast cancer, considering the unique challenges faced by rural and underserved populations 

Faculty

Harold J. Burstein, MD, PhD 
Professor of Medicine 
Harvard Medical School 
Medical Oncologist 
Dana-Farber Cancer Institute 
Boston, MA

Chris Prakash, MD 
Director, Quality Services - Texas Oncology 
Chair, Medical Oncology Quality - Texas Oncology 
President, Texas Society of Clinical Oncology 
Medical Director, Texas Oncology - Paris 
Paris, TX 

Joint Accreditation Statement

In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation 

Physician Continuing Medical Education
Talem Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.75 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

Continuing Pharmacy Education
Talem Health designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008332-0000-24-064-H01-P)
Type of Activity: Application

Disclosure of Conflicts of Interest 

Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

All relevant financial relationships have been mitigated.  

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity: 

Faculty

Harold J. Burstein, MD, has no relevant financial relationships to disclose. 

Chris Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc. 

Planners, Managers, and Reviewer 

The Talem Health planners, managers, and reviewer have nothing to disclose.

Instructions for Participation and Credit 

This activity is offered at no cost to participants. To receive CME credit, participants must: 

1. Read the CME/CE information, including learning objectives and disclosure statements. 
2. Complete the pre-test. 
3. View the online activity. 
4. Complete the post-test and evaluation form. 

A post-test score of 75% or higher is required to obtain credit. Your certificate will be made available for immediate download. 

Course Viewing Requirements 

Supported Browsers: 
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above 
Google Chrome 28.0+ for Windows, Mac OS, or Linux 
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux 
Safari 6.0+ for Mac OSX 10.7 and above 

Supported Phones & Tablets: 
Android 4.0.3 and above 
iPhone/iPad with iOS 6.1 or above 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.  

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.  

©RME Collaborative, a division of Talem Health, LLC. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited. 

Media 

Internet activity 

Fee Information 

There is no fee for this educational activity. 

Contact Information 

For questions about this activity, please contact RME Collaborative (a division of Talem Health) at 800-913-9370 or cme@cmeruralhealth.com.